CN106491621A - Friedolanostanes is preparing treatment or the application in preventing canker sore medicine - Google Patents
Friedolanostanes is preparing treatment or the application in preventing canker sore medicine Download PDFInfo
- Publication number
- CN106491621A CN106491621A CN201610821945.9A CN201610821945A CN106491621A CN 106491621 A CN106491621 A CN 106491621A CN 201610821945 A CN201610821945 A CN 201610821945A CN 106491621 A CN106491621 A CN 106491621A
- Authority
- CN
- China
- Prior art keywords
- friedolanostanes
- canker sore
- application
- medicine
- preparing treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to Friedolanostanes is preparing treatment or the application in preventing canker sore medicine, belong to first public, as framework types belong to brand-new framework types, and which treats canker sore activity by force, possess prominent substantive distinguishing features, be simultaneously used for treating canker sore obviously with significant progressive.
Description
Technical field
The present invention relates to the new application of compound Friedolanostanes, more particularly to Friedolanostanes is in system
Application in standby treatment or preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of illness rate office diseases of oral mucosa.
Sircus (1975) investigates 1587 people, and illness rate is 20%.As can be seen here, canker sore patient is a very huge group
Body.The cause of disease of recurrent oral ulceration is complicated, still indefinite so far, may with virus infection, bacterium infection and body in
The factors such as parasecretion, immune dysfunction are relevant.The primary treatment measure of canker sore includes local treatment and whole body therapeutic,
As local treatment toxic and side effect is relatively low, the people for therefore having obtained people can.The buccal tablets that the local for occurring in recent years uses
Although carry, easy to use, mouthfeel and compliance preferably, such as lysozyme lozenge, watermelon crystal buccal tablet, Dobell etc., these medicines
Thing emphasizes particularly on different fields at aspects such as sterilization, anti-inflammatory, pain relievings.
Compound Friedolanostanes according to the present invention be one deliver within 2012 (Saranyoo Klaiklay,
et al.,Friedolanostanes and xanthones from the twigs of Garcinia
Hombroniana.Phytochemistry, 85 (2013) 161 166.) noval chemical compound, the compound have brand-new skeleton
Type, is only capable of suppressing tumor cell proliferation (Saranyoo Klaiklay, et al., Friedolanostanes and
xanthones from the twigs of Garcinia hombroniana.Phytochemistry,85(2013)161–
The purposes of 166., Friedolanostanes according to the present invention in preparation treatment or preventing canker sore medicine belongs to first
Open.
Content of the invention
It is an object of the invention to treating or prevention according to not finding in existing Friedolanostanes researchs which has
The present situation of the report of canker sore, there is provided Friedolanostanes answering in treatment or preventing canker sore medicine is prepared
With.
Shown in the compound Friedolanostanes structures such as formula (I)：
Purposes of the Friedolanostanes according to the present invention in preparation treatment or preventing canker sore medicine belongs to
First public, as framework types belong to brand-new framework types, and which is treated or preventing canker sore activity is strong, possesses prominent
The substantive distinguishing features for going out, are simultaneously used for treatment or preventing canker sore obviously has significant progress.
Specific embodiment
The preparation method of compound Friedolanostanes involved in the present invention is referring to document (Saranyoo
Klaiklay, et al., Friedolanostanes and xanthones from the twigs of Garcinia
hombroniana.Phytochemistry,85(2013)161–166.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by concrete real
Any restriction of example is applied, but is defined in the claims.
Embodiment 1：The preparation of compound Friedolanostanes tablets involved in the present invention：
Take 5 g of compound Friedolanostanes and add 195 grams of dextrin, mix, Conventional compression makes 1000.
Embodiment 2：The preparation of compound Friedolanostanes capsules involved in the present invention：
Take 5 g of compound Friedolanostanes and add 195 grams of starch, mix, encapsulated make 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Test example 1：Friedolanostanes anti-oral ulcer experimental studies
1st, test objective：Oral ulcer model is manufactured with phenol, the certain number of times of Oral ulcer model rat is given daily
Friedolanostanes, observes the effect whether Friedolanostanes is reduced ulcer.
2nd, test medicine and reagent
Dobell (Beijing Sihuan Medicine Science and Technology Co., Ltd)；Phenol
Animal：Wistar rats, male, 240～280g of body weight, Nanjing Medical University's Experimental Animal Center.
3rd, test method
Rat 50 is taken, male, 240～280g of body weight, 10% chloral hydrate anesthesia, dosage：0.35ml/100g, anesthesia
Afterwards by the plastic dropper (internal diameter of 90% phenol cotton balls：3mm) lower end is flat on the cheek film at rats with left bicker about 1mm, is burnt
30min is burnt, that is, sees the white infringement of about 3mm at this.It is grouped after 24 hours immediately, 10 per group, point 5 groups, i.e. model group (auxiliary material
4 times/day, not drug containing)；Friedolanostanes high dose groups (4 times/day, 0.5mg/ time)；In Friedolanostanes
Dosage (4 times/day, 0.1mg/ time)；Friedolanostanes low dose groups (4 times/day, 0.02mg/ time)；Positive controls：
Dobell group (4 times/day, 0.5mg/ time).Friedolanostanes and Dobell lozenge using front smashing, be administered with
Flap coverage is degree.Successive administration 5 days, the next day observation ulcer area size (diameter with ulcer after being administered before administration and every time
Meter) and ulcer healing situation (ulcer being visible by naked eyes is considered as healing), first administration to last dose is recorded as 1 respectively, 2,
3rd, 4,5,6 days.Ulcer area size is checked with t, and ulcer healing rate is checked with X2.
4th, result of the test
Ulcer area compares (table 1)：Friedolanostanes high dose groups were compared with model group, from administration the 3rd day
To off-test, corresponding to compare daily has significant difference；Dobell group is compared with model group, plays test within the 3rd day from administration
Terminate, corresponding to compare daily has significant difference；Friedolanostanes middle dose groups are compared with model group, from administration the 3rd
It plays off-test, and corresponding to compare daily has significant difference；Friedolanostanes low dose groups are compared with model group,
Off-test is played within 5th day from administration, corresponding to compare daily has significant difference；Friedolanostanes middle dose groups and China
Plain piece group compares, and plays off-test within the 1st day from administration, and corresponding to compare daily has significant difference.
Impact of the table 1 to rat ulcer area
Note：Compare with model group, * p<0.05, * p<0.01.
Healing rate (table 2)：Model group and Friedolanostanes low dose groups play off-test on the 1st day from administration,
Ulcer does not heal；And Friedolanostanes high dose groups just have ulcer healing from administration the 4th day, to off-test,
Up to 90%；Dobell group has ulcer healing, to off-test, up to 60% from administration the 4th day；In Friedolanostanes
Dosage group has ulcer healing, to off-test, up to 40% from administration the 5th day.
Impact of the table 2 to rat ulcer healing time
Note：Compare with model group, * p<0.05, * p<0.01.
5th, conclusion
Friedolanostanes has the effect for being obviously promoted canker sore healing.
Claims (1)
- Applications of the 1.Friedolanostanes in treatment or preventing canker sore medicine, the compound Shown in Friedolanostanes structures such as formula (I)：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610821945.9A CN106491621A (en) | 2016-09-14 | 2016-09-14 | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610821945.9A CN106491621A (en) | 2016-09-14 | 2016-09-14 | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106491621A true CN106491621A (en) | 2017-03-15 |
Family
ID=58291370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610821945.9A Pending CN106491621A (en) | 2016-09-14 | 2016-09-14 | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106491621A (en) |
-
2016
- 2016-09-14 CN CN201610821945.9A patent/CN106491621A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN106491621A (en) | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN106619604A (en) | Medicine for treating or preventing dental ulcer, and application of medicine | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN105412109A (en) | Application of Biscarpamontamine B in preparing drugs for treating or preventing dental ulcers | |
| CN105147676A (en) | Medicine for preventing or treating dental ulcer | |
| CN105287543A (en) | Application of strynuxlines B to prepare medicines treating or preventing oral ulcer | |
| CN105434428A (en) | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN107837278A (en) | Orientin is preparing the application in treating or preventing stomatocace medicine | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN107854472A (en) | Isovitexin is preparing the application in treating or preventing stomatocace medicine | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN110179860A (en) | A kind of drug of anti-epileptic, preparation method and the usage | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170315 |
|
| WD01 | Invention patent application deemed withdrawn after publication |